Home
Screener
Insiders
Rankings
Sign in
Create account
Insiders
· Profile
Leonard Frank X
Chief Executive Officer at NovoCure. Filing since 2 Mar 2021.
CIK 0001822879
Company
Date
Role
Action
Shares
Amount
Of holding
NVCR
NovoCure Ltd
4 Jun 2026
Chief Executive Officer
Sold at will
34,273
$614.63K
6.9%
NVCR
NovoCure Ltd
4 Mar 2026
Chief Executive Officer
Sold at will
5,607
$74.60K
1.1%
NVCR
NovoCure Ltd
2 Mar 2026
Chief Executive Officer
Sold at will
7,232
$97.58K
2.0%
NVCR
NovoCure Ltd
27 Feb 2026
Chief Executive Officer
Sold at will
9,734
$133.00K
2.8%
NVCR
NovoCure Ltd
2 Jun 2025
EVP, Pres., Novocure Oncology
Sold on a plan
30,196
$528.41K
15.2%
NVCR
NovoCure Ltd
3 Mar 2025
EVP, Pres., Novocure Oncology
Sold at will
2,527
$46.84K
1.7%
NVCR
NovoCure Ltd
28 Feb 2025
EVP, Pres., Novocure Oncology
Sold at will
2,770
$50.65K
1.9%
NVCR
NovoCure Ltd
27 Feb 2025
EVP, Pres., Novocure Oncology
Sold at will
12,266
$245.61K
7.6%
NVCR
NovoCure Ltd
1 Nov 2024
EVP, Pres., Novocure Oncology
Sold at will
598
$9.53K
0.4%
NVCR
NovoCure Ltd
4 Mar 2024
EVP, Pres., Novocure Oncology
Sold at will
840
$13.45K
0.5%
NVCR
NovoCure Ltd
1 Mar 2024
EVP, Pres., Novocure Oncology
Sold at will
1,679
$26.91K
1.0%
NVCR
NovoCure Ltd
28 Feb 2024
EVP, Pres., Novocure Oncology
Sold at will
2,078
$33.54K
1.3%
NVCR
NovoCure Ltd
7 Mar 2023
President, CNS Cancers US
Sold, plan not stated
8,318
$625.21K
13.3%
NVCR
NovoCure Ltd
3 Mar 2023
President, CNS Cancers US
Sold, plan not stated
7,350
$562.82K
10.5%
NVCR
NovoCure Ltd
2 Mar 2023
President, CNS Cancers US
Sold, plan not stated
4,951
$373.11K
7.8%
NVCR
NovoCure Ltd
1 Mar 2023
President, CNS Cancers US
Sold, plan not stated
1,684
$128.59K
2.6%
NVCR
NovoCure Ltd
5 Jan 2023
President, CNS Cancers US
Sold, plan not stated
39,507
$4.43M
46.1%
NVCR
NovoCure Ltd
13 Oct 2022
President, CNS Cancers US
Sold, plan not stated
6,754
$513.37K
13.4%
NVCR
NovoCure Ltd
6 Oct 2022
President, CNS Cancers US
Sold, plan not stated
6,754
$569.83K
11.8%
NVCR
NovoCure Ltd
29 Sep 2022
President, CNS Cancers US
Sold, plan not stated
6,754
$522.42K
10.6%
NVCR
NovoCure Ltd
22 Sep 2022
President, CNS Cancers US
Sold, plan not stated
6,754
$520.06K
9.6%
NVCR
NovoCure Ltd
15 Sep 2022
Chief Development Officer
Sold, plan not stated
12,271
$1.09M
14.8%
NVCR
NovoCure Ltd
9 Sep 2022
Chief Development Officer
Sold, plan not stated
1,863
$163.94K
2.2%
NVCR
NovoCure Ltd
6 Sep 2022
Chief Development Officer
Sold, plan not stated
1,384
$108.74K
1.6%
NVCR
NovoCure Ltd
2 Sep 2022
Chief Development Officer
Sold, plan not stated
584
$46.16K
0.7%
NVCR
NovoCure Ltd
1 Sep 2022
Chief Development Officer
Sold, plan not stated
14,212
$1.10M
13.9%
NVCR
NovoCure Ltd
2 Aug 2022
Chief Development Officer
Sold, plan not stated
414
$28.84K
0.4%
NVCR
NovoCure Ltd
8 Mar 2022
Chief Development Officer
Sold, plan not stated
744
$52.15K
0.7%
NVCR
NovoCure Ltd
4 Mar 2022
Chief Development Officer
Sold, plan not stated
555
$39.08K
0.5%
NVCR
NovoCure Ltd
3 Mar 2022
Chief Development Officer
Sold, plan not stated
930
$69.28K
0.9%
NVCR
NovoCure Ltd
2 Sep 2021
Chief Development Officer
Sold, plan not stated
540
$74.65K
0.6%
NVCR
NovoCure Ltd
3 Aug 2021
Chief Development Officer
Sold, plan not stated
328
$49.01K
0.4%
NVCR
NovoCure Ltd
2 Aug 2021
Chief Development Officer
Sold, plan not stated
713
$106.51K
0.8%
NVCR
NovoCure Ltd
8 Mar 2021
Chief Development Officer
Sold, plan not stated
765
$100.07K
0.8%
NVCR
NovoCure Ltd
4 Mar 2021
Chief Development Officer
Sold, plan not stated
567
$77.99K
0.6%
NVCR
NovoCure Ltd
2 Mar 2021
Chief Development Officer
Sold, plan not stated
430
$65.38K
0.5%
36 decisions on file.
